Genitourinary Cancers Symposium

San Francisco, CA—The early termination of clinical trials is a tremendous waste of resources and can leave patients with cancer with no improved treatment options.
Read Article

San Francisco, CA—Radiation added to hormone therapy with antiandrogens extended cancer-specific survival, as well as overall survival, when used as the primary treatment of patients with locally advanced or high-risk prostate cancer.
Read Article

San Francisco, CA—The use of angiotensin system inhibitors (ASIs) improved survival in patients with metastatic renal-cell carcinoma (mRCC) by 9 months, according to a retrospective pooled analysis of several clinical trials presented at the 2014 Genitourinary Cancers Symposium.
Read Article

San Francisco, CA—Enzalutamide (Xtandi) prolonged survival and delayed radiographic progression of disease in men who had not received chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Read Article

San Francisco, CA—In a retrospective long-term comparative analysis of 3 prostate cancer treatment strategies, treatment with external beam radiation therapy (EBRT) was more toxic and costlier than prostatectomy and brachytherapy, according to Cleveland Clinic researchers who presented their data at the 2012 annual Genitourinary Cancers Symposium.
Read Article

San Francisco, CA—A personalized form of immunotherapy added to sunitinib (Sutent) treatment prolonged survival to beyond 30 months in almost half of patients with newly diagnosed, unfavorable-risk metastatic renal-cell carcinoma (mRCC), according to the results of an open-label phase 2 study presented at the 2012 Genitourinary Cancer Symposium.
Read Article

San Francisco, CA—The dosage of axitinib, the standard second-line treatment for metastatic renal-cell carcinoma (mRCC), should be uptitrated in those patients who fail to achieve therapeutic blood levels on the standard 5-mg daily dosage, according to a new analysis of an international randomized trial presented at the 2012 Genitourinary Cancers Symposium.
Read Article

San Francisco, CA—More than 1 in 10 patients with metastatic prostate cancer never receive anticancer treatment for their disease, according to an examination of the National Cancer Database.
Read Article

San Francisco, CA—A large number of patients with metastatic renal-cell carcinoma (mRCC) are ineligible for clinical trials and their clinical outcomes are inferior to those of patients who are trial eligible, according to a study presented at the 2012 Genitouri nary Cancers Symposium.
Read Article

San Francisco, CA—Nonpharmacologic strategies for prevention of cancer are potentially attractive and costeffective, but success stories are few.
Read Article

Page 2 of 4